Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.

O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM
J Clin Oncol. 2011 29 (17): 2350-6

PMID: 21519015 · PMCID: PMC3107750 · DOI:10.1200/JCO.2010.33.9432

MeSH Terms (10)

Aged Benzimidazoles Carcinoma, Hepatocellular Female Humans Liver Neoplasms Male MAP Kinase Kinase 1 MAP Kinase Kinase 2 Middle Aged

Connections (1)

This publication is referenced by other Labnodes entities: